42 citations
,
December 1976 in “PubMed” Cyproterone acetate and ethinylestradiol effectively reduce hirsutism and acne in women.
May 2023 in “Journal of Pharmaceutical Innovation”
April 2023 in “Cancer research” KRTAP2-3 could help predict cancer recurrence by identifying specific cancer cells.
1 citations
,
June 2026 in “Dermato” Ritlecitinib is effective for treating alopecia areata, showing significant hair regrowth with mild side effects.
October 2025 in “Quantum Journal of Medical and Health Sciences” Tridax procumbens is a plant with many health benefits, including healing, protecting the liver, fighting infections, and promoting hair growth.
January 2021 in “Asian Journal of Pharmaceutical and Clinical Research” FT-Raman spectroscopy is effective for identifying drug polymorphs, ensuring quality and stability.
18 citations
,
May 1988 in “Journal of The American Academy of Dermatology” Itraconazole helps improve tough skin infections but may not prevent them from coming back.
October 2025 in “INSOLOGI Jurnal Sains dan Teknologi” Pacing leaf extracts can promote hair growth in rabbits, but minoxidil works better.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
July 2014 in “Americanae (AECID Library)” Tridax procumbens and Ouratea spectabilis can affect other plants' growth and have antioxidant benefits.
Cepharanthine could be a strong antiviral against COVID-19.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery” January 2024 in “AIP conference proceedings” February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
1 citations
,
August 2025 Drug repurposing can speed up and reduce costs in drug discovery, especially for cancer treatment.
July 2023 in “Journal of exploratory research in pharmacology” A new psoriasis lotion called "Psorisbye" improved symptoms in a patient within one week.
July 2013 in “Pharmaceutical Regulatory Affairs Open Access” Invasomes with 0.5% limonene greatly improve skin delivery of finasteride.
June 2026 in “British Journal of Dermatology” Regional prescribing of ritlecitinib mostly follows national guidance, but psychological assessments and consistent scoring need improvement.
25 citations
,
July 2013 in “Actas Dermo-Sifiliográficas” Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.
6 citations
,
June 2022 in “Journal of Clinical Medicine” Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.
January 2025 in “Bandung Conference Series Pharmacy” Tin leaf extract in solid shampoo can effectively reduce oxidative stress on hair and scalp.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
January 2026 in “The Pharma Innovation” A kitten with mange was cured using selamectin, shampoo, supplements, and ointment.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
22 citations
,
May 2003 in “Planta Medica” Torilin from Torilis japonica can inhibit testosterone 5α-reductase but is less effective than finasteride.
7 citations
,
September 2007 Valproate sustained-release is effective and generally safe for short-term treatment of new partial epilepsy.